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tology department with complaint of chronic acne on the
face, back and buttocks with severe sinus tracts and
depressed scar formation for 20 years (Fig. 1A). Long-term
oral minocycline provided some relief, but new crops of
lesions continued to develop periodically. He started to
suffer from intermittent chest pain and palpitation during
the past 5 years. Repeated 24-hour-electrocardiography
monitoring and echocardiography were unremarkable. In
addition, episodic polyarthralgia over the bilateral tempo-
romandibular joint, left shoulder, and left ankle were
noted in recent years. Laboratory studies revealed a mild
increase in the erythrocyte sedimentation rate (11 mm,
normal: <10 mm) and mild decreases in immunoglobulin G
(656 mg/dL, normal: 751e1560 mg/dL), immunoglobulin M
(44.4 mg/dL, normal: 46e304 mg/dL), and complement 3
(72.7 mg/dL, normal: 79e152 mg/dL). X-ray of the chest,
left ankle, and skull, as well as computed tomography of
the head and anterior chest wall were all unremarkable.
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mandible, and distal ends of the tibia and fibula (Fig. 1B).
Skin biopsy from an inflammatory cystic lesion revealed
ruptured follicular pustules with neutrophil-predominant
inflammation (Fig. 1D and E). By combining the course of
illness, histopathology, and laboratory findings, the diag-
nosis of SAPHO syndrome was established.
The patient was initially treated with sulfasalazine,
etoricoxib, methotrexate, and prednisolone for 5 months
with only mild improvement. Subsequently, etanercept
(25 mg twice a week) and isotretinoin (20 mg once daily)
were prescribed. After 6 weeks, the patient experienced
neither chest pain nor joint pain. Scattered flares of cystic
acne were still noted. Etanercept (25 mg twice a week) and
isotretinoin (20 mg once daily) were prescribed for another
3 months. Etanercept was then tapered to 25 mg once a
week for 1 month, and 25 mg every other week for another
2 months. Isotretinoin was tapered to 10 mg once daily. The
patient experienced occasional flare ups of chest pain and
acne. Abnormal values for the erythrocyte sedimentation
rate, immunoglobulins, and complement 3 became normal.
Follow-up bone scintigraphy revealed regress in the distal
ends of the left tibia and fibula (Fig. 1C).
SAPHO syndrome, an acronym for synovitis, acne, pus-
tulosis, hyperostosis, and osteitis, is characterized by both
cutaneous lesions and osteoarticular manifestation. The& Formosan Medical Association. All rights reserved.
Figure 1 (A) Chronic, severe nodulocystic acne on face with severe sinus tracts and depressed scar; bone scintigraphy (B) before
and (C) after treatment. (B) Uptake of left parietal skull, the sternocostoclavicular and manubriosternal joints, maxilla, mandible,
and distal ends of the tibia and fibula. (C) Regression in distal ends of left tibia and fibula after 6 months treatment of etanercept
(black arrows). (D) A ruptured follicle with dense inflammatory infiltrates and pseudoepithelial hyperplasia (H&E, 20). (E)
Neutrophil-predominant inflammation (H&E, 400).
SAPHO syndrome successfully treated with etanercept 563dermatological conditions may occur concomitantly, pre-
cede, or follow bone involvement.1 Benhamou et al first
proposed the diagnostic criteria for SAPHO syndrome. The
presence of any one of these four presentations is sufficient
for a diagnosis: (1) osteoarticular manifestation of acne
conglobata, acne fulminans, or suppurative hydradenitis;
(2) osteoarticular manifestation of palmoplantar pustulosis;
(3) hyperostosis with or without dermatosis; or (4) chronic
recurrent multifocal osteomyelitis involving axial or pe-
ripheral skeleton, with or without dermatosis.2 Imaging
plays an important role in defining osteoarticular lesions.
Classic radiographic findings are hyperostosis and osteitis.
Bone scintigraphy is useful for detection of clinically silent
lesions. A characteristic high tracer uptake in the sterno-
costoclavicular region, known as the bull’s head sign, is
virtually pathognomonic.1,3
The pathogenesis of SAPHO syndrome remains poorly
understood. Some authors classify this syndrome in the
group of seronegative spondyloarthropathies, whereas
others consider it a form of reactive osteitis.1Current treatment of SAPHO syndrome remains a great
challenge. Several drugs, including antibiotics, nonsteroids
anti-inflammatory drugs, corticosteroids, sulfasalazine,
methotrexate, cyclosporin, retinoids have been adminis-
tered with conflicting results.1 Recent reports showed
antitumor necrosis factor (TNF)-alpha agents such as
infliximab and etanercept are effective therapies.4 In our
patient, a combination of etanercept and isotretinoin
seemed to be a promising therapy for his osteoarticular
complaints whereas cutaneous involvement responded less
favorably. The possible mechanism is that chronic devas-
tating acne conglobata can lead to severe, irrevocable
damage to the follicular canal and result in disfiguring
scarring. However, these structural abnormalities, which
cannot be corrected by etanercept and isotretinoin, make
the patient still prone to recurrent follicular obstruction by
sebum and further pustules and abscess formation.5 Timely
diagnosis and appropriate treatment of acne conglobata
and SAPHO syndrome are essential, and etanercept is a safe
and effective option in refractory SAPHO syndrome.
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